All In Biotech

Drug Trial Radar · NCT02755545

A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments

A Multi-Center Clinical Trial to Evaluate the Efficacy of Two Acne Treatments

Last checked: Nov 20, 2026Latest source record: Dec 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

May 1, 2016

Primary completion

Apr 4, 2017

Study completion Apr 4, 2017

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Apr 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of 2 acne treatments for 24 weeks of use in adult men and women with mild to moderate facial acne, at least 5 inflammatory lesions, and at least 10 - 100 non-inflammatory lesions.

Conditions

  • Acne

Interventions

  • Product ADrug

    Product A applied topically to the entire face or other affected area of the skin once daily

  • Product BDrug

    Product B applied topically to affected area of the skin 1 to 3 times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Total Lesions at Week 12Time frame: Baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stephens & Associates, Inc. Texas Research Center

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.